OPTIMAL VERSUS MAXIMALLY TOLERATED DOSE IN CANCER-CHEMOTHERAPY TREATMENT

被引：3

作者：

MARKMAN, M ^{[1
]}

机构：

[1] CLEVELAND CLIN FDN,DEPT HEMATOL MED ONCOL,CLEVELAND,OH 44195

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 1993年 / 119卷 / 10期

关键词：

D O I：

10.1007/BF01372720

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：576 / 577

页数：2

共 15 条

[11] PHASE-II STUDY OF TAXOL IN PATIENTS WITH UNTREATED ADVANCED NON-SMALL-CELL LUNG-CANCER [J].

MURPHY, WK ;

FOSSELLA, FV ;

WINN, RJ ;

SHIN, DM ;

HYNES, HE ;

GROSS, HM ;

DAVILLA, E ;

LEIMERT, J ;

DHINGRA, H ;

RABER, MN ;

KRAKOFF, IH ;

HONG, WK .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :384-388

[12]

ROWINSKY EK, 1988, CANCER RES, V48, P4093

[13] TAXOL - A NOVEL INVESTIGATIONAL ANTIMICROTUBULE AGENT [J].

ROWINSKY, EK ;

CAZENAVE, LA ;

DONEHOWER, RC .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (15) :1247-1259

[14] PHASE-I STUDY OF TAXOL AND GRANULOCYTE COLONY-STIMULATING FACTOR IN PATIENTS WITH REFRACTORY OVARIAN-CANCER [J].

SAROSY, G ;

KOHN, E ;

STONE, DA ;

ROTHENBERG, M ;

JACOB, J ;

ADAMO, DO ;

OGNIBENE, FP ;

CUNNION, RE ;

REED, E .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1165-1170

[15]

SEIDMAN A, 1992, P AN M AM SOC CLIN, V11, P59

← 1 2 →